Join Trial Testing Once-Weekly Insulin for Type 1 Diabetes

A clinical trial is recruiting adults with type 1 diabetes who use multiple daily insulin injections. The study will compare the safety and effectiveness of once-weekly and daily insulin, both in combination with mealtime insulin.

Join Trial Testing Ways To Improve Hypoglycemia Unawareness

Join Trial Testing Automated Insulin Delivery for Cystic Fibrosis-Related Diabetes

A clinical trial is recruiting teens and adults with cystic fibrosis-related diabetes to see if the iLet Bionic Pancreas AID system can help improve blood sugar management.

Type 1 Diabetes Clinical Trials

Current clinical trials for people with type 1 diabetes are exploring treatments to restore beta cell function, prevent and treat complications, and reduce the burden of blood sugar management. See if you're eligible to enroll.

Afrezza Inhaled Insulin for Type 1 and Type 2 Diabetes

Survodutide Shows Promising Weight Loss and Cardiometabolic Benefits

Survodutide is a new investigational dual GLP-1 injectable medication being tested for weight management in clinical trials.

Tzield (Teplizumab) to Delay Type 1 Diabetes

Tzield has been shown to delay the onset of type 1 diabetes by an average of two years. Here’s more about screening and whether treatment may be right for you.

Join Trial Testing Once-Weekly Insulin for Type 1 Diabetes

A clinical trial is recruiting adults with type 1 diabetes who use multiple daily insulin injections. The study will compare the safety and effectiveness of once-weekly and daily insulin, both in combination with mealtime insulin.

Afrezza Inhaled Insulin for Type 1 and Type 2 Diabetes

Top Diabetes News: ATTD 2026

Big new insights on diabetes treatments, technology, and risks emerged from the 2026 Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona. Here’s what matters most for people living with diabetes.

Medtronic MiniMed 780G: Overview, Features, and News

Key takeaways: * The Medtronic MiniMed 780G AID system automatically adjusts insulin doses from an insulin pump every five minutes based on CGM readings * Medtronic's Instinct, a CGM that uses Freestyle Libre technology, and a new CGM called the Simplera Sync [https://diatribe.org/diabetes-technology/medtronic-simplera-cgm-how-it-works-features-and-latest-updates] are now available in the US.   * In September, the FDA approved the MiniMed 780G for use in people with type 2 diabetes. 

Diabetes Jeopardy! Test Your Knowledge

twiist: How It Works, Features, Latest Updates

The twiist automated insulin delivery system is based on Tidepool Loop, a user-friendly algorithm that grew out of the open-source diabetes community. Approved for people with type 1 diabetes ages 6 and up, twiist automates dosing, allows users to set a glucose target as low as 87 mg/dL, and offers meal presets to better deal with different food types (pizza, for example).

Zepbound (Tirzepatide) for Chronic Weight Management: Uses, Side Effects, and Cost

Key takeaways: * Zepbound targets two key hormone receptors (GIP and GLP-1) to help reduce excess weight. * Mounjaro and Zepbound (generic name tirzepatide) are approved to treat several type 2 diabetes and weight loss, respectively. * The latest: Eli Lilly recently announced that the lowest dose of the drug will be available at $299, with the highest doses at $449.

FDA Warns Against Compounded Semaglutide for Diabetes, Weight Loss

Key takeaways:  * The FDA has recently issued warnings to companies offering compounded medications with false or misleading claims that their medications are FDA-approved and equivalent in safety to approved drugs like Ozempic. * Compounded drugs are created by combining or altering ingredients to customize medications for specific individuals. While compounded drugs are sometimes prescribed by healthcare providers for people who can't afford or access a certain drug, they are not FDA-approved. * The FDA previously issued an alert to healthcare providers, compound pharmacies, and patients about recent overdoses associated with compounded injectable semaglutide.

Vertex Continues Multiple Paths To Potential Islet Cell Cure

After ending the VX-264 trial, which used a device to protect lab-grown islet cells, the company will continue research on therapies with and without the need for immunosuppressive drugs.